• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 6, 2024
Distillery Therapeutics

Inhibiting NLRC5 for hemolytic and inflammatory diseases

Read More
BioCentury | Apr 25, 2024
Product Development

Innate immune activators among first-in-human debuts at AACR

Spotlight on early-stage solid tumor trials with emerging innate immune targets: ALPK1 and ENPP1
Read More
BioCentury | Apr 20, 2024
Discovery & Translation

Science spotlight: New immune evasion pathway, plus BBB breakdown mechanism and more

BioCentury’s roundup of translational innovations
Read More
BioCentury | Jan 6, 2024
Discovery & Translation

Immunotherapy, hold the intestinal inflammation; plus Chugai and more

BioCentury’s roundup of translational innovations
Read More
BioCentury | Aug 15, 2023
Distillery Therapeutics

Blocking the DRP1-FIS1 interaction for diseases with mitochondrial dysfunction

Read More
BioCentury | Jul 18, 2023
Distillery Therapeutics

Keratin-derived peptides for corneal inflammation and infection

Read More
BioCentury | Jun 2, 2023
Emerging Company Profile

Actym: programming microbes to treat solid tumors

Backed by Boehringer Ingelheim and Panacea, Actym is engineering microbes to enable safe, systemic delivery
Read More
BioCentury | Nov 3, 2022
Product Development

GSK sees commercial opportunity in antimicrobial resistance

Pharma stops trials of antibiotic gepotidacin early for efficacy as it deepens commitment to fighting AMR
Read More
BioCentury | Dec 3, 2021
Distillery Therapeutics

Targeting PTH1R for epididymitis and orchitis 

Read More
BioCentury | Apr 1, 2020
Product Development

Chinese data propel InflaRx anti-complement mAb into clinic for severe COVID-19 pneumonia

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
Read More
Items per page:
1 - 10 of 257